MiMedx Group, Inc. (NASDAQ:MDXG) Receives Consensus Rating of “Buy” from Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been given an average rating of “Buy” by the five brokerages that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $12.00.

MDXG has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Craig Hallum cut their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Finally, StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds and other institutional investors have recently made changes to their positions in MDXG. Headlands Technologies LLC acquired a new position in shares of MiMedx Group in the first quarter worth approximately $27,000. Isthmus Partners LLC lifted its stake in shares of MiMedx Group by 30.4% in the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after acquiring an additional 91,714 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of MiMedx Group in the second quarter worth approximately $40,000. Quest Partners LLC acquired a new position in shares of MiMedx Group in the second quarter worth approximately $81,000. Finally, Entropy Technologies LP acquired a new position in MiMedx Group in the first quarter valued at approximately $99,000. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Stock Down 1.6 %

Shares of NASDAQ MDXG opened at $6.13 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85. MiMedx Group has a 52 week low of $5.57 and a 52 week high of $9.27. The stock has a market capitalization of $904.81 million, a P/E ratio of 13.93 and a beta of 1.98. The stock’s fifty day moving average is $6.67 and its 200 day moving average is $7.01.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The firm had revenue of $87.21 million for the quarter, compared to analysts’ expectations of $88.44 million. Sell-side analysts forecast that MiMedx Group will post 0.26 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.